gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

FDA Approved Opdivo for Metastatic Small-Cell Lung Cancer

October 2018 Vol 4 No 5

In August 2018, the FDA approved the immunotherapy Opdivo (nivolumab; from Bristol-Myers Squibb) for the treatment of patients with metastatic (spreading) small-cell lung cancer that progressed after platinum-based chemotherapy and at least 1 other therapy.

Opdivo was previously approved by the FDA for patients with non–small-cell lung cancer, the most common type of lung cancer. This new approval makes this immunotherapy also available for patients with small-cell lung cancer, which has fewer treatment options.

This approval was based on results from a clinical trial of 109 patients with or without PD-1 expression who had metastatic small-cell lung cancer that progressed after chemotherapy and at least 1 other therapy.

Overall, in 13 patients with small-cell lung cancer, the cancer responded to treatment with Opdivo, and the responses lasted between 6 months to more than 18 months. This new approval for Opdivo now offers patients with small-cell lung cancer access to immunotherapy, an important addition to the treatment options available for patients with this type of lung cancer.

The side effects with Opdivo in this study were similar to those seen in other studies, and 10% of patients discontinued treatment because of side effects.

Recommended For You
Lung Cancer
Drugs for Lung Cancer
Here are the drugs and financial support services available to patients receiving treatment for Lung Cancer.
Genetics & CancerLung CancerPatient Stories
Using My Lung Cancer Story to Advocate for Change in Minority Communities
By Brandi Bryant
After getting tested for genetic abnormalities, Brandi Bryant learned she had the ALK genetic mutation, which increases the risk for lung cancer. This information resulted in important changes in her treatment and led her to become an advocate for genetic testing, especially among minority communities.
Lung Cancer
Tecentriq plus Chemotherapy Approved as First Therapy for Metastatic Lung Cancer without EGFR or ALK Mutations
Late in 2019, the FDA approved the combination of immunotherapy plus chemotherapy as the first-line treatment for patients with non–small-cell lung cancer that does not harbor EGFR or ALK mutations, which are often associated with lung cancer.
Lung Cancer
What Do I Need to Know? A Guide for the Newly Diagnosed Person with Lung Cancer
By Claudia T Miller, BSN, RN, OCN, ONN-CG
The treatment landscape of lung cancer has changed dramatically in the past 5 years. New immunotherapies have significantly improved survival. Learn about your diagnosis and the current treatment options.
Last modified: October 27, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country